We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Merck, Roche Announces Distribution Agreement
News

Merck, Roche Announces Distribution Agreement

Merck, Roche Announces Distribution Agreement
News

Merck, Roche Announces Distribution Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Merck, Roche Announces Distribution Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Merck has announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015. The addition of the Kapa portfolio strengthens Merck’s existing distribution relationship with Roche by providing one of the most complementary suites of high-performance tools for PCR and qPCR available in the industry.

“The alliance extension with Roche will offer our customers greater access to novel products via our world-class distribution channel,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “These enzymes represent a significant advantage over commercially available DNA polymerases and thus offer the potential for entirely new PCR applications.”

Under the terms of the agreement, Merck will employ its sales, marketing and e-commerce expertise and leverage the strength of its relationships with the scientific community to present and distribute Kapa PCR and quantitative PCR reagents and kits. The distribution agreement includes all geographies except the U.S., Japan and Brazil. Financial details were not disclosed.

Roche inked the global exclusive distribution agreement for its Biochemical Reagents portfolio with Sigma-Aldrich in July 2015. Following the acquisition of Sigma-Aldrich by Merck in the same year, this agreement became an important part of Merck, driving growth in its life science business and offering premier brand tools for genomics, proteomics and cell analysis.

The novel PCR enzymes offered under the expanded distribution agreement have improved tolerance to common PCR inhibitors, increased speed and specific activity, and higher fidelity. These characteristics enable higher quality results and improved workflows. Transition of Kapa’s PCR and qPCR portfolios to Merck is expected to be completed by January 1, 2017. In the interim, these products will continue to be available through existing Kapa channels.

Source: Story from Merck KGaA. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.

Advertisement